This anti-S1 SARS-CoV-2 nanobody was developed by the team of Alejandro Rojas-Fernandez at the Institute of Medicine from the Universidad Austral de Chile. NanoTag acquired the exclusive license to produce this nanobody and make it available or research and development purposes. The FluoTag-Q anti-S1 SARS-CoV-2 is based on the W25 clone, which has a sub-nanomolar affinity for the SARS-CoV-2 S1 protein receptor binding domain (RBD) and can neutralize infections as it efficiently competes with ACE-2 receptor binding.
In FluoTag-X two fluorophore molecules are site-specifically coupled to each FluoTag molecule which ensures bright signals. Owing to the small size of the FluoTags, the distance between the target epitope and each fluorophore is below 4 nm.
In comparison to detection systems using conventional antibodies, FluoTag-X can thus improve the localization accuracy by 10-15 nm. Both features - superior brightness and precise fluorophore placement - render the FluoTag-X products excellent tools for all microscopy techniques.